NCT01059786 2025-06-12Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell LeukemiaNational Institutes of Health Clinical Center (CC)Phase 2 Active not recruiting69 enrolled 12 charts